Prime Medicine
PRME
183 hedge funds and large institutions have $337M invested in Prime Medicine in 2025 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 67 increasing their positions, 40 reducing their positions, and 26 closing their positions.
69% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 26
68% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 40
10% more funds holding
Funds holding: 167 → 183 (+16)
8% less call options, than puts
Call options by funds: $3.21M | Put options by funds: $3.5M
14.87% less ownership
Funds ownership: 68.62% → 53.75% (-15%)
34% less capital invested
Capital invested by funds: $512M → $337M (-$175M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$16.9M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$13.7M |
| 3 |
BlackRock
New York
|
+$11.6M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$9.5M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$16.6M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$15.6M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$14.3M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$8.55M |
| 5 |
Millennium Management
New York
|
-$6.08M |
PRME Hedge Fund Activity: Q4 2025 in Review
183 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Prime Medicine (PRME) for Q4 2025, worth a combined $337M — down 34% from $512M a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new PRME positions and 26 closed out — a net gain of 18 holders — while 67 added to existing stakes and 40 trimmed.
The largest buyer was State Street, adding an estimated $16.9M. The largest seller was RA Capital Management, exiting entirely with an estimated $16.6M sold.
- 183 institutional investors held Prime Medicine (PRME) as of Q4 2025, up from 167 in Q3 2025.
- Funds reported $337M of Prime Medicine stock for Q4 2025, down 34% quarter-over-quarter.
- 44 funds opened new Prime Medicine positions in Q4 2025 and 26 closed out, a net change of +18 holders.
- The largest Prime Medicine buyer in Q4 2025 was State Street, an estimated $16.9M added.
- The largest Prime Medicine seller in Q4 2025 was RA Capital Management, an estimated $16.6M sold.
Based on aggregated 13F filings for Q4 2025.